

SPEAKER 1: As I've emphasized, the treatment of a MAC disease is complex. I welcome the addition to the treatment modality, inhaled liposomal amikacin. It's a brilliant step forward, allowing us to use a drug which has been proven to be efficacious over the years in a formulation which is much less toxic, that is inhaled versus intravenous.

It's a wonderful addition to the basic armamentarium of the three drugs-- rifampin, macrolide, and ethambutol. So we have four good drugs, and then we have a variety of other drugs that we can use under certain situations that are, to say the least, not FDA approved and certainly not standard treatment.